Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $251.65
    -1.75 (-0.69%)

    Market Cap: $37.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biogen Inc (BIIB) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Biogen (BIIB) is expected to report earnings on Feb 4, 2027. In the quarter ended Sep 30, 2026, Biogen reported EPS of $2.62, above the $2.06 estimate. It beat the EPS estimate in each of the last 18 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    93%(37/40)
    Avg Surprise
    +11.69%
    Streak
    18 Q

    Upcoming Estimates

    Reports Feb 4, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$2.81
    Range$2.39 - $3.45
    33 analysts
    Revenue Consensus
    $2.65B
    Range$2.38B - $3.55B
    32 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.57
    Range$2.93 - $4.18
    13 analysts
    EPS Estimate DriftChange to current
    90d ago$3.65-2.2%
    60d ago$3.65-2.0%
    30d ago$3.65-2.1%
    7d ago$3.55+0.7%
    Current$3.57
    Revenue Consensus
    $2.61B
    Range$2.37B - $2.73B
    12 analysts

    Next Report

    BIIB has an expected report date of Feb 4, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 41.2% above the $1.99 reported for the quarter ended Dec 31, 2025.

    BIIB Earnings Call

    The latest BIIB earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BIIB beat 37 and missed 3. Revenue for the quarter ended Sep 30, 2026 was $2.80B, up 10.7% from $2.53B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.62$2.06$1.44 - $2.31+27.18%Beat-45.5%272 up, 2 downOct 28, 2026$2.80B
    Jun 30, 2026$3.60$3.04-$21.10 - $3.80+18.42%Beat-34.2%271 up, 0 downJul 29, 2026$2.74B
    Mar 31, 2026$3.57$2.89$1.45 - $4.68+23.53%Beat+18.2%284 up, 13 downApr 29, 2026$2.48B
    Dec 31, 2025$1.99$1.62$1.31 - $2.24+22.84%Beat-42.2%269 up, 5 downFeb 6, 2026$2.28B
    Sep 30, 2025$4.81$3.88$3.18 - $4.60+23.97%Beat+17.9%268 up, 6 downOct 30, 2025$2.53B
    Jun 30, 2025$5.47$3.88$3.59 - $4.12+40.98%Beat+3.6%262 up, 14 downJul 31, 2025$2.65B
    Mar 31, 2025$3.02$2.95$1.94 - $4.03+2.37%Beat-17.7%241 up, 13 downMay 1, 2025$2.43B
    Dec 31, 2024$3.44$3.36$2.77 - $3.68+2.38%Beat+4.2%262 up, 11 downFeb 12, 2025$2.45B
    Sep 30, 2024$4.08$3.79$3.52 - $4.35+7.65%Beat-6.4%256 up, 0 downOct 30, 2024$2.47B
    Jun 30, 2024$5.28$4.03$3.46 - $6.04+31.02%Beat+31.3%278 up, 1 downAug 1, 2024$2.46B
    Mar 31, 2024$3.67$3.46$3.06 - $3.96+6.07%Beat+7.9%289 up, 1 downApr 24, 2024$2.29B
    Dec 31, 2023$3.30$3.18$2.75 - $3.86+3.77%Beat-18.5%279 up, 0 downFeb 13, 2024$2.39B
    Sep 30, 2023$4.36$3.98$3.11 - $4.50+9.55%Beat-8.6%256 up, 2 downNov 8, 2023$2.53B
    Jun 30, 2023$4.02$3.76$3.07 - $4.16+6.91%Beat-23.4%256 up, 4 downJul 25, 2023$2.46B
    Mar 31, 2023$3.40$3.28$2.16 - $3.88+3.66%Beat-6.1%242 up, 2 downApr 25, 2023$2.46B
    Dec 31, 2022$4.05$3.48$3.17 - $4.18+16.38%Beat+19.5%2610 up, 0 downFeb 15, 2023$2.54B
    Sep 30, 2022$4.77$4.13$3.57 - $4.81+15.50%Beat0.0%267 up, 3 downOct 25, 2022$2.51B
    Jun 30, 2022$5.25$4.07$3.24 - $4.75+28.99%Beat-7.6%264 up, 4 downJul 20, 2022$2.59B
    Mar 31, 2022$3.62$4.36$3.52 - $5.36-16.97%Miss-32.2%258 up, 0 downMay 3, 2022$2.53B
    Dec 31, 2021$3.39$3.37$2.88 - $4.14+0.59%Beat-26.0%287 up, 0 downFeb 3, 2022$2.73B
    Sep 30, 2021$4.77$4.10$3.65 - $4.69+16.34%Beat-46.0%23N/AOct 20, 2021$2.78B
    Jun 30, 2021$5.68$4.60$3.73 - $5.31+23.48%Beat-44.6%25N/AJul 22, 2021$2.77B
    Mar 31, 2021$5.34$4.94$4.05 - $5.89+8.10%Beat-41.6%24N/AApr 22, 2021$2.69B
    Dec 31, 2020$4.58$4.80$4.14 - $7.14-4.58%Miss-45.1%28N/AFeb 3, 2021$2.85B
    Sep 30, 2020$8.84$8.05$7.61 - $8.99+9.81%Beat-3.6%28N/AOct 21, 2020$3.38B
    Jun 30, 2020$10.26$8.00$7.09 - $9.07+28.25%Beat+12.1%25N/AJul 22, 2020$3.68B
    Mar 31, 2020$9.14$7.69$5.63 - $8.65+18.86%Beat+30.9%28N/AApr 22, 2020$3.53B
    Dec 31, 2019$8.34$8.08$6.47 - $9.32+3.22%Beat+19.3%29N/AJan 30, 2020$3.67B
    Sep 30, 2019$9.17$8.27$7.80 - $9.15+10.88%Beat+23.9%27N/AOct 22, 2019$3.60B
    Jun 30, 2019$9.15$7.53$6.74 - $8.11+21.51%Beat+57.8%27N/AJul 23, 2019$3.62B
    Mar 31, 2019$6.98$6.96$6.38 - $7.47+0.29%Beat+15.4%25N/AApr 24, 2019$3.49B
    Dec 31, 2018$6.99$6.72$6.01 - $7.65+4.02%Beat+32.9%26N/AJan 29, 2019$3.53B
    Sep 30, 2018$7.40$6.76$6.53 - $7.19+9.47%Beat+17.3%26N/AOct 23, 2018$3.44B
    Jun 30, 2018$5.80$5.14$3.95 - $6.44+12.84%Beat+15.1%26N/AJul 24, 2018$3.36B
    Mar 31, 2018$6.05$5.94$5.54 - $6.26+1.85%Beat+16.3%26N/AApr 24, 2018$3.13B
    Dec 31, 2017$5.26$5.45$4.82 - $6.08-3.49%Miss+4.4%30N/AJan 25, 2018$3.31B
    Sep 30, 2017$6.31$5.72$5.10 - $6.16+10.31%Beat+21.6%26N/AOct 24, 2017$3.08B
    Jun 30, 2017$5.04$4.37$3.92 - $5.58+15.33%Beat-3.3%25N/AJul 25, 2017$3.08B
    Mar 31, 2017$5.20$4.97N/A+4.63%Beat+8.6%N/AN/AApr 25, 2017$2.81B
    Dec 31, 2016$5.04$4.96N/A+1.61%Beat+12.0%N/AN/AJan 26, 2017$2.87B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $15.29, down 7.2% from the year before. It was $20.23 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$15.29-7.2%
    Dec 31, 2024$16.47+9.2%
    Dec 31, 2023$15.08-14.8%
    Dec 31, 2022$17.69-7.8%
    Dec 31, 2021$19.18-41.6%
    Dec 31, 2020$32.82-2.4%
    Dec 31, 2019$33.64+28.2%
    Dec 31, 2018$26.24+20.3%
    Dec 31, 2017$21.81+7.8%
    Dec 31, 2016$20.23N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,48521
    2026Q2Jun 30, 202610,27517
    2026Q1Mar 31, 20269,09818
    2025Q4Dec 31, 20259,52017
    2025Q3Sep 30, 20257,93716
    2025Q2Jun 30, 20256,42714
    2025Q1Mar 31, 20257,37914
    2024Q4Dec 31, 20245,81715

    2026Q3 Earnings Call

    Opening remarks

    Tim Power Head of Investor Relations Thanks, Cynthia. Good morning, everybody. Welcome to Biogen's third quarter 2026 earnings call. During this call, we will make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide you with a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed on this call, can be found in the Investors section of biogen.com. We have also posted the slides to our website that we will use during the call. On today's call, I am joined by our President and Chief Executive Officer, Christopher A. Viehbacher; Dr. Priya Singhal, Head of Development; Robin Kramer, our Chief Financial Officer; and Alisha Alaimo, President, North America, who is also available for the Q&A section of the call. Christopher will make some opening comments, and we will move to the Q&A session. To allow us to get through as many questions as possible, we will ask you to kindly limit yourself to just one question. I will now hand the call over to Christopher.

    Christopher A. Viehbacher President and CEO All right. Thank you, Tim. Good morning, everybody. A very strong quarter this morning. It is actually one of those quarters where the numbers almost speak for themselves. Total revenue grew 11% year over year. Now, of course, that is not all organic. That was significantly benefited by the acquisition of Apellis. But I would also say that the acquisition and integration of Apellis has gone even better than expected. The integration team has, I think, been able to identify and realize cost synergies faster than we thought. Alisha is here, and I have to give her a lot of credit for her leadership in really ensuring that the Apellis team has felt welcome within Biogen. I think the most credit goes to the people from Apellis who have joined Biogen, placed their faith in Biogen, and have been able to look past the inevitable distraction that comes with an integration and really focus on our customers, the health care professionals, and patients that we serve. So, as I look at it, obviously, Apellis has certainly helped us. Our industry has embraced bolt-on acquisitions over the years. But one of the things I have learned is that if you are going to do a bolt-on, you have to bolt it on to something solid. One of the things that we have been working on at Biogen over the last several years is improving our cost base, but also really launching our growth products and getting those performing at a top level.

    Frequently Asked Questions About BIIB

    When is Biogen's next earnings date?

    Biogen's next earnings report is expected for Feb 4, 2027.

    Did BIIB beat earnings estimates last quarter?

    Yes. Biogen reported EPS of $2.62 for the quarter ended Sep 30, 2026, above the $2.06 estimate, a 27.18% surprise.

    What EPS do analysts expect from BIIB next quarter?

    The consensus EPS estimate for Biogen for the quarter ending Dec 31, 2026 is $2.81 from 33 analysts, with estimates from $2.39 to $3.45.

    How often does BIIB beat earnings estimates?

    Biogen beat the EPS estimate in each of the last 18 quarters, with an average surprise of +16.18%.